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intRoDuction
Surgical series have demonstrated that 20–30% of small 
renal masses (SRMs) are benign upon final pathology 
assessment after excision,1 and as a consequence it is ever 
pressing to obtain histological evidence to avoid over and 
unnecessary treatment. The role of renal tumour biopsy 
(RTB) has been acknowledged recently, but there many 
areas which remain poorly understood including its role in 
active surveillance of SRM <4 cm as a pre-defined patient 
group, and especially the handling of indeterminate results 
in evaluating the diagnostic accuracy of this technique.
Recent systematic review and meta-analyses2,3 aimed 
to assess the diagnostic performance and safety of renal 
biopsy are both fraught with many methodological 
limitations. The studies included a large number of orig-
inal papers which biopsied renal masses >4 cm with the 
largest biopsied mass of 32 cm.4–7 In a sensitivity analysis 
limited to studies reporting on SRMs, (<4 cm), Marconi 
et al2 failed to mention whether non-diagnostic results 
were treated as negative or were excluded from analysis in 
the included studies of their reported systematic review. 
Therefore, the generalizability of these findings to patients 
with SRMs less than 4 cm is limited and clinical challenge 
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objective: To determine the safety and diagnostic accu-
racy of renal tumour biopsies in a defined population of 
small renal masses (SRMs) only <4 cm using 3 × 2 table, 
intention to diagnose approach. 3 × 2 table approach 
examines indeterminate results as a separate category 
rather than pushing these through traditional 2 × 2 table 
(four-cell matrix) approach.
methods: A highly sensitive search was performed in 
the Cochrane Library, Database of Abstracts of Reviews 
of Effects; MEDLINE and MEDLINE in Process, EMBASE 
and conference proceedings (1966–2016) for the acqui-
sition of data on the diagnostic accuracy and complica-
tions of RTB in patients with SRM <4 cm. Methodological 
quality and risk of bias was assessed using QUADAS-2. 
Test characteristics were calculated using conventional 2 
× 2 contingency table analysis excluding non-diagnostic 
biopsies, and an intention-to-diagnose approach with a 
3 × 2 table for pooled estimates of the sensitivity and 
specificity.
Results: A total of 20 studies were included with a total 
sample size of 974. The pooled estimates for sensitivity 
and specificity of RTB based upon univariate analysis 
using 2 × 2 table observed sensitivity 0.952 [confidence 
interval (CI) 0.908–0.979] and specificity 0.824 (CI 
0.566–0.962). Using the 3 × 2 table and intention-to-di-
agnose principle, sensitivity 0.947 (CI 0.925–0.965) and 
specificity 0.609 (CI 0.385–0.803) decreased.
conclusion: RTB in SRMs (<4 cm) is associated with a 
high diagnostic sensitivity but poor specificity when 
non-diagnostic results are included by a 3 × 2 table 
for analysis (intention to diagnose approach). Risk of 
non-diagnostic results and poor quality of research 
need addressing through future studies, preferably by a 
well-designed prospective study appropriately powered 
for diagnostic accuracy using valid reference standards.
advances in knowledge: A comprehensive synthesis 
of literature on image-guided biopsies in SRMs using a 
different methodology and study design.
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in decision-making for indeterminate results remains a core 
issue in contemporary urological practice. It could be argued, 
that a larger biopsy target will improve sensitivity and accuracy 
outcomes because evidence suggests that tumour size plays a 
pivotal role, and small tumours are pushed by the biopsy needle 
instead of penetration to obtain adequate tissue.8,9 With this in 
mind, a contrary view can put forward that that larger tumours 
are often necrotic and this could diminish accuracy, however 
no evidence has been provided to support this assertion in the 
previous reviews in this area.4–7
Simel et al10 described a 3 × 2 contingency table approach to 
deal with non-diagnostic results (non-positive and non-neg-
ative)—a common scenario in RTB during clinical deci-
sion-making. The traditional approach has been to report 
outcomes of RTB using 2 × 2 tables (four-cell matrix) and 
making a number of assumptions such as treating non-diag-
nostic results as negative, excluding them from the analysis or 
treating these as positive. These approaches have the poten-
tial of leading to spurious diagnostic accuracy outcome for 
diagnostic tests, both sensitivity and specificity.11 Figure  1 
summarises the intention to diagnose principle used in this 
study. We considered, if the reference standard (histopathology 
of excised mass) proved to be positive for cancer, then an inde-
terminate RTB result was false-negative (FN) and, in contrast, 
if the reference standard showed no cancer (benign), then the 
indeterminate result was considered false-positive (FP). In 
other words if an indeterminate test missed a true-positive 
(TP), it was considered as FP and if it missed a true-negative 
(TN), it was considered as FP. This is similar to the approach 
used by Schuetz et al11 in a meta-analysis of coronary CT 
angiography.
The primary objective of the study was to determine the diagnostic 
accuracy of percutaneous image-guided renal biopsy for detecting 
renal malignancy in individuals with only small (<4 cm), solid and 
enhancing renal masses employing the 3 × 2 table approach to 
minimize overestimation of diagnostic accuracy as described in the 
previous studies. The secondary objectives were to: (1) determine 
the rate of complications of the biopsy procedure such as post-pro-
cedural bleeding, infection (local or systemic), arteriovenous fistula 
formation, renal loss or seeding, and (2) establish the accuracy of 
the biopsy procedure to determine cancer grade and (3) establish 
the accuracy of biopsy procedure to determine pathological type of 
renal cell carcinoma (e.g. papillary, clear cell carcinoma).
methoDS anD mateRialS
Types of studies
All observational studies reporting on image-guided biopsy in 
SRMs (<4 cm) were included. Studies with sufficient data to 
produce 2 × 2 and 3 × 2 contingency tables were included in the 
meta-analysis. Studies were excluded reporting on ex vivo kidney 
biopsies, non-image guided biopsies of renal masses such as 
those with the endoscopic (or laparoscopic) approach and those 
conducted on animals.
Participants
Safety and diagnostic accuracy of image guided biopsies was 
assessed in patients with SRMs in adults with small (<4 cm) 
solid renal mass and signs of contrast enhancement (CT, MRI). 
Studies were excluded with participants with known metastatic 
disease, either from renal cell carcinoma or other primary (e.g. 
breast cancer) cancers, and lesions >4 cm.
Index tests
Image-guided biopsy (obtaining a tissue sample using a needle 
under imaging guidance) in a renal mass which included renal 
core biopsies. Studies with indeterminate biopsy were also eval-
uated for patient outcomes. Inconclusive results were handled as 
a separate category as uninterpretable, intermediate and inde-
terminate. We also analysed these results as test–test strategy 
underpinned by clinical practice of repeating the index test in 
cases of inconclusive results.
Figure 1.  Explanation of 3 × 2 table analysis for the non-diagnostic results.
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Target conditions
Pathology-confirmed renal cell carcinoma.
Reference standards
We regarded histopathology of resection specimen (nephrectomy 
or partial nephrectomy) as the reference standard. In those studies 
where histopathology of the resected tissue was not available, we 
utilized long-term follow-up information (3 years) as an indirect 
assessment of the presence of malignant renal mass. The devel-
opment of metastatic disease that is clinically determined to be 
of renal origin or the delayed surgical removal of the mass with 
confirmed malignancy was interpreted as evidence of a FN biopsy; 
the remainder were treated as TN. We excluded studies with no 
histopathological confirmation through subsequent resection of 
target condition or those with shorter follow up of less than 3 years. 
Growth in size alone was not used as a reference standard as benign 
lesions are known to exhibit growth upon serial imaging.
Search methods for identification of studies
Electronic searches
We performed an extensive electronic search to identify reports 
of relevant published and ongoing studies as well as grey liter-
ature, and recent meeting abstracts. A highly sensitive search 
strategy was developed using both appropriate subject head-
ings and text word terms that reflect the clinical condition, 
interventional procedure (renal mass biopsy and subsequent 
management) and study designs that are within the scope of this 
project. Our search strategy is provided in Supplemental Table 
1. This strategy was tested against a list of references to verify 
that these relevant records were found. The following databases 
were consulted: the Cochrane Library (Wiley) including the 
Cochrane Central Register of Controlled Trials (CENTRAL), 
Cochrane Database of Systematic Reviews (CDSR) and Data-
base of Abstracts of Reviews of Effects (DARE); MEDLINE and 
MEDLINE in Process (Ovid SP) (from 1948 onwards); EMBASE 
(Ovid) including conference proceedings (from 1947 onwards); 
BIOSIS Citation Index (from 1985 onwards); and Web of Science 
including the ISI Science Citation Index and Index to Confer-
ence proceedings (http://ipscience.  thomsonreuters. com) (from 
1900 onwards). We applied no methodological filter to minimize 
any risk of missing relevant studies.12
Searching other resources
We searched for ongoing studies at  ClinicalTrials. gov . We also 
searched for conference abstracts via the conference proceed-
ings sections in the Web of Science and EMBASE searches. The 
research team screened the diagnostic database Medion  as well 
as the Aggressive Research Intelligence Facility databases (http://
www. birmingham. ac. uk/ research/ activity/ mds/ projects/ HaPS/ 
PHEB/ ARIF/ databases/ index. aspx). An internet search included 
the websites of the American Urological Association (http://
www. auanet. org/) and European Association of Urology (http:// 
uroweb. org/) from the year 2010 onwards as well as manufac-
turers of biopsy equipment.
Data collection and analysis
Selection of studies
All observational studies reporting on image -guided biopsy in 
SRMs and with data sufficient to populate 2 × 2 and 3 × 2 tables 
for diagnostic accuracy assessment were included. Two review 
authors (CP, JG) screened titles and abstracts independently and 
in duplicate. All disagreements were resolved by discussion or by 
involving a third review author (GN) as an arbiter. A pre-defined 
electronic spreadsheet was used to assess and document studies 
for inclusion and exclusion according to the aforementioned 
selection criteria (criteria for considering studies for this review).
Data extraction and management
Four review authors (JG, CP, CSB, AA) independently performed 
data extraction of full-text papers using a pre-defined electronic 
spreadsheet. A fifth review author (GN) independently verified 
all the extracted data. Any discrepancy was resolved by discus-
sions. Where necessary, we contacted study authors to obtain raw 
data. We used Cochrane statistical software13 for further anal-
ysis. The reviewers abstracted information from all the included 
studies. The extracted information included: (a) the distribution 
of diagnoses in groups of patients with malignant and benign 
diseases; (b) the size of the SRMs; (c) the location of the lesions 
(upper, mid- or lower polar); peripheral or central in relation to 
renal parenchyma (d) the type of needle; (e) the type of radiolog-
ical guidance; (f) whether a uropathologist was consulted during 
or prior to the procedure; (g) the reference standard utilised 
by the investigators (h) the type and number of complications 
(pneumothorax and bleeding) associated with the biopsy; and (i) 
the final results related to the accuracy of the test.
Assessment of methodological quality
Study quality was assessed using the Quality Assessment of Diag-
nostic Accuracy Studies (QUADAS)−2 quality checklist.14–16 
Four review authors (JG, CP, CSB, AA) independently scored 
each item as “yes”, “no” or “unclear”. All quality appraisal and any 
discrepancies were resolved by discussion with the fifth author 
(GN). Briefly, the included studies were assessed in four main 
key domains: (1) patient selection; (2) index test; (3) reference 
standard; (4) flow and timing. We evaluated study validity by 
systematically taking into account each of the potential sources 
of biases: work-up bias, by excluding patients from the analysis 
because they were not submitted to the reference standard proce-
dure; review bias which is introduced when the test result was 
not verified by the reference standard procedure; and the test 
review bias which is introduced when the observers are aware of 
either the clinical condition of the patient or the final diagnosis.
Statistical analysis and data synthesis
The index test used in this review was to provide a binary outcome 
(presence of or absence of malignant condition). A univariate 
random-effects model was employed to obtain summary esti-
mates of the sensitivity and specificity of the test.17,18 Review 
Manager software19 was for primary analyses and Meta-DiSc 
(http://www. hrc. es/ investigacion/ metadisc_ en. htm), a publicly 
available software program for the diagnostic accuracy of tests 
and for secondary analyses.20 We calculated summary diagnostic 
performance values including 95% confidence intervals (CIs) 
from standard data of a 2 × 2 table (after excluding indetermi-
nate results) or the 3 × 2 table, including indeterminate results 
either in the “FN” or the “FP” cell of a 2 × 2 table according to 
the results of the reference standard (intention-to-diagnose prin-
ciple). Where possible, the quality items relating to spectrum of 
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patients, technical problems in the conduction of index testing 
using different imaging modalities leading to verification and 
detection biases, and other domains in the QUADAS-2 tool were 
considered as potential covariates for sensitivity analysis.12,14,15
Assessment of reporting bias
The funnel plot was applied to determine the possibility of 
reporting bias and small study effects using plots of log diag-
nostic odds ratio vs 1/ESS1/2, where ESS is “effective sample 
size” defined as (4 n + n2)/(n1 + n2); moreover a test for asym-
metry was assessed using regression and rank correlation tests.21 
However, testing for reporting bias and small study effects may 
not be especially useful in the context of studies of diagnostic 
tests.22
ReSultS
Results of the search
A total of 7212 titles and abstracts were identified by the liter-
ature search. Of the 85 full-text publications, 65 were excluded 
for the following reasons: renal lesions >4 cm;23–31 no final histo-
pathology as reference standard;9,32–40 no description of tumour 
size,41,42 RTB not performed,43,44 not SRM’s, and45–54 descriptive 
narrative papers and one ex-vivo study55 (Figure 1 for PRISMA). 
This list is available from the authors on request. The remaining 
20 publications were reviewed in full: two prospective longitu-
dinal studies and eighteen retrospective studies (Table  1). The 
included studies were carried out in a number of international 
centres, mainly located in European countries or in the USA 
(16/20; 80%). The data collection ranged between 1982 and 2013, 
mainly retrospective in design (19/20; 90%. The sample sizes 
ranged from 5 to 529, with a total sample size of 974 of partici-
pants that had final pathology available as a reference standard.
Operating characteristic of renal tumour biopsy in 
SRMs
Across all the included studies (Table 1) data was tabulated into 
TP, TN, FN, and FP, At the individual patient level, indeterminate 
biopsy results were tabulated as positive and negative (Table 2). 
Due to the small sample sizes of the available data as a reference 
standard it was not possible to conduct individual analysis of 
each of the primary studies.
Overall pooled sensitivity (0.952, CI 0.908–0.979) and specificity 
(0.824, CI 0.566–0.962) were considered to be at a satisfactory 
diagnostic rate when using a 2 × 2 table contingency. The pooled 
estimates for sensitivity and specificity of core biopsy based upon 
bivariate analysis significantly decreased for the 3 × 2 table contin-
gency at a value of 0.945 (CI 0.920–0.960) and 0.609 (CI 0.397–
0.800), p < 0.001, respectively (Figure 2). The median prevalence 
of non-diagnostic core biopsy was three patients [interquartile 
range (IQR 2–12)] across the patient series, and two studies did 
not report indeterminate biopsy numbers.56,57 There were 171 
patients with indeterminate results (171/974; 17.5%). The effects 
of different ways of handling indeterminate biopsies results upon 
pooled diagnostic accuracy values are depicted in Figure 3.
There is very limited available data on the  accuracy of the 
subtype and Fuhrman grade of RTB when compared to final 
surgical histopathology. Four studies reported58–61 grade concor-
dance ranging from 90 to 98%, with a substantial agreement κ 
of 0.69 (substantial agreement), however, tumour grade accu-
racy assignment of SRM <4 cm was more challenging. Fuhrman 
grade was accurately assigned in 50/72 (69%) when compared to 
nephrectomy specimens, upgraded in 17 (25%) and downgraded 
in 5 (7%).60 Data identifying tumours were graded erroneously 
as low (I or II) or high (III or IV), with accuracy for grade eval-
uation 69.8% (44/63).61 Similar rates reported elsewhere 11/21 
(52.3%).58 Other series reported robust grade assignment with 
RTB at 93%.56
Complications
All the included studies reported on the prevalence of complica-
tions post-RTB, with the exception of a few.8,56,62–64  Four studies 
reported no complications57,61,65,66  with no seeding at mean 
follow up 18 months,67 and longer at 28 months (IQR 11–53) 
or upon final histopathology.1,63,65,68 One reported suspected 
seeding69 over the course of follow up (2 years and 6 months) for 
a liposarcoma. Across the included studies, three patients (3/974; 
0.3%) required blood transfusions58,60  because of post-opera-
tive bleeding, one patient was admitted due to gross haematuria 
and urinary clots,59  and one patient required percutaneous 
angioembolization,57  though all recovered without sequelae. In 
another patient, a 2 cm intrarenal haematoma was mistaken for 
a tumour and excised at laparoscopic partial nephrectomy and 
subsequently, patient required to undergo a radical nephrectomy 
to remove renal (clear) cell carcinoma.60  Minor complications 
included hypotension59  pain64,67,70  wound infection  perirenal 
haematomas1,64,65  and small pneumothorax1,59  all managed 
conservatively. Minor complication rates ranged from 2.1%,65 
8.5%  10.4%, to 20%.64 No mortality was reported across all 
studies related to RTB.
Risk of bias and quality assessment
The methodology quality assessed by the QUADAS-2 tool 
across the 20 included studies is summarised in Table 3. Overall, 
there was a high risk of bias across all the included studies. 
The majority of the included studies were retrospective 19/20; 
90%), and none of the included studies featured sample size 
calculations when estimating power for diagnostic accuracy in 
RTB. Most sample sizes were small, with a lack of clinical and 
demographic information to sufficiently characterise the patient 
population. Moreover, most studies did not detail the follow-up 
duration of the included participants over time, with the excep-
tion of,66,67,70,76 with the longest follow-up of just over 2 years. 
Only one study reported the time interval of RTB to the date of 
surgery72 (48 days, IQR 29–68), and the remaining studies were 
at risk of flow and timing bias. None of the included studies 
described the learning curve of the interventional radiologist 
or pathologist, which could inevitably influence RTB outcomes. 
37.8% (974/2573) participants in the included studies had refer-
ence standards reported. However, more than half the partici-
pants (1546/2573; 62.2%) did not have reference standards listed; 
raising concerns of verification-bias as pathology of the resected 
SRMs was not available (opting for cryotherapy, RFA and AS), 
therefore the FP and FN rates remain unknown. Hence, these 
patients were excluded in the pooled sensitivity and specificity 
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analysis. Finally, none of the included studies reported blinding 
of the outcome assessor/s.
Imaging modalities, needle gauges and number of 
biopsies
CT imaging modality and ultrasound scan was the most 
commonly reported approach to RTB,1,58–60,62,69,74 real-time 3D 
fluoroscopy CT56,76 and MRI.67 The majority of studies used a 
18G needle, with the biggest size report as 14G.73 The number of 
cores ranged from 1 to 5 across of a number of studies.60,63,72,74,77 
Based on the small sample sizes, there was no usable data to 
conduct sensitivity analysis to explore the impact of proce-
dural approaches on diagnostic yield. The procedural time and 
cost-consequence were not addressed in any of the included 
studies.
DiScuSSion
We set out to affirm the significance of the diagnostic accuracy of 
RTB in SRMs (<4 cm), specifically to address the existing bias and 
methodological problems of handling indeterminate results.2 In 
a well-defined patient population of SRMs; RTB exhibited a high 
overall diagnostic rate (95%). However, specificity of the inter-
vention remains low (61%) when we applied the intention-to-di-
agnose principle using a 3 × 2 table approach. From a clinical 
perspective, by transforming the 2 × 2 table into a 3 × 2 table, 
we reported all results accordingly and hence outcomes are fully 
transparent and summarised. This approach significantly altered 
diagnostic accuracy of RTB particularly in terms of specificity 
of the results. This may help in clinical decision-making and 
exploring the true clinical potential of RTB. Low rates of true 
negative (specificity) may raise a possibility of missing a malig-
nant tumour using RTB which clinically is not acceptable as this 
provides false reassurance. Moreover, it limits choices of inter-
ventions and scope of discussion/options with patients diag-
nosed with incidental SRMs specifically for active surveillance. 
A strength of the current study was the definition of TP and TN 
because RTB’s were only compared to final surgical specimen 
histopathology, and the intention-to-diagnosis principle using 
3 × 2 table analysis (Figure  1). A summary of including inde-
terminate results as FPs or FNs according to reference standard 
offers transparent evidence for potential clinical use of the RTB 
test most adequately.
While it is clear that there is no agreed upon policy in the litera-
ture regarding how to handle indeterminate results of RTB, our 
review showed that 17.5% participants were reported to have 
indeterminate outcomes of first RTB attempts in 18 studies. 
Again, there was lack of clarity as to how these results were 
handled at the analysis level. Moreover, only 10 (10/20; 50%) of 
the included studies provided enough data to calculate alterna-
tive the 3 × 2 tables. None of the included studies used 3 × 2 table 
approach to analyse the outcomes of RTB.
Although overall, the diagnostic accuracy of RTB, RCC subtypes 
appeared to be reliable, the agreement between tumour grade at 
biopsy and upon the final surgical specimen had a much poorer 
performance, and this has been reported even in a meta-anal-
ysis with much larger tumour >4 cm targets.2 Grade of tumour, A
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a surrogate marker for tumour aggressiveness, is an independent 
and powerful prognostic predictor of cancer-specific outcomes.77 
Poor performance of RTB in our study may be based on varia-
tions in the level of expertise of the reporting pathologist, quality 
of biopsy material and operator of the RTB procedure.56 In the 
included studies, very little or no information was detailed on 
these parameters. It is a common clinical observation that there 
is a learning curve for this intervention, which again was not esti-
mated in any of the included studies. We pooled data from studies 
with available reference standard, however across the majority of 
patients in the included studies, they did not have their masses 
surgically removed and therefore, “definitively” determining the 
relationship between indeterminate or negative biopsy and the 
presence of cancer was impossible for these individuals. This 
summary of evidence should be considered while applying RTB 
in active surveillance of SRMs.
In the present study, we were unable to perform sensitivity anal-
yses on the performance of RTB for the following factors: loca-
tion of the tumour (anterior/posterior); lesion’s echogenicity/
enhancement; amount of adipose tissue; skin to tumour depth; 
expertise of radiologist/pathologist; imaging modality; number 
of passes and needle gauge; small sample size and lack of usable 
data. However, intuitively the diagnostic rate should increase 
with the number of biopsy cores. Across the vast majority of 
studies “multiple passes” were performed to achieve a histological 
diagnosis. However, this may increase the risk of complications, 
but evidence does not clearly delineate the number of passes 
Figure 2. Flow of the diagnostic review.
Figure 3. Diagnostic accuracy of image guided biopsies in small renal masses (<4 cm). CI, confidence interval.
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required or indeed the optimum technique or imaging modality. 
Multivariate analyses from previous studies have suggested 
factors that can predict diagnosis of SRM biopsy include tumour 
type, the presence of a cystic lesion, odds ratio of 13.9 (95% CI 
= 3.78–50.7; p < 0.0001) and tumour size, and for every 1 cm 
increase in diameter the odds ratio for diagnostic biopsy was 3.11 
(95% CI = 1.54–6.28, p = 0.002).59
Unfortunately, the methodological quality of the included 
studies was poor, and the level of evidence underscores that 
despite many years of experience in RTB, there is a pressing 
need for a multicentre international collaboration to prospec-
tively examine the RTB in SRM <4 cm. There were a number 
of patients who underwent AS and ablative therapies whereby, 
ultimately the prevalence of FP, FN will remain unknown. With 
a very limited follow-up, the median was reported at 25 months. 
Moreover, the majority were at risk of flow and timing bias, with 
only one study describing the duration between RTB procedure 
and surgery. Finally, studies were at risk of selection bias and 
through the use of different reference standards (differential-ver-
ification bias) including clinical and demographic differences in 
patients, clinical follow-up schedules, and RTB protocol-based 
approaches. Despite these limitations, we followed a robust, 
transparent methodology for reproducibility with strict study 
selection to address the role of RTB in SRMs, specifically <4 cm. 
We acknowledge that our findings are constrained because of the 
methodological limitations of the included studies. However, this 
systematic review has enabled a broad summary of the evidence, 
which facilitated refinement of future research directions and 
clinical implications.
Implication for clinical practice and future research
There are a number of uncertainties in the body of evidence of 
research to guide clinical practice:
(1) There are a number of studies focusing on outcome of 
intervention; mostly retrospective in design without prior 
protocols, power calculation and independent data assessors. 
Guidelines for clinical practice are mainly based on a large 
number of studies with risk of biases. Future improved 
designed prospective studies with better executions are 
necessary.
Table 3.  Risk of bias summary
Study Risk of bias  Applicability concerns 
Patient 
selection Index test 
 Reference 
standard 
Flow and 
timing 
Patient 
selection   Index test 
Reference 
standard 
Abe and Saitoh71        
Neuzillet et al61         
Eshed et al8 
      
Shah et al63  
       
Li et al65        
Volpe et al72         
Wang et al69         
Chyhrai et al73         
Leveridge et al59         
Kroeze et al74        
Menogue et al60         
Salem et al75         
Millet et al56        
Walton et al58        
Halverson et al73        
Park et al71        
Garnon et al69         
Richard et al70        
Hu et al64        
Menhadji et al66        
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